Filtered By:
Infectious Disease: Pandemics
Drug: Actemra

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 260 results found since Jan 2013.

A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
Authors: Solis-García Del Pozo J, Galindo MF, Nava E, Jordán J Abstract The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find treatments that are effective against this disease that the World Health Organization calls COVID-19. In severe cases of COVID-19, there is an increase in cytokines, among which IL-6 seems to play an important role. A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. Also, a search of ongoing trials registered at clinicaltrials.gov was performed. We found very little pu...
Source: European Review for Medical and Pharmacological Sciences - July 28, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea
J Korean Med Sci. 2022 Dec 19;37(49):e353. doi: 10.3346/jkms.2022.37.e353.ABSTRACTSince 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, and the coronavirus disease 2019 (COVID-19) pandemic currently continues. In response to this unprecedented pandemic, several researchers and medical staff have struggled to find appropriate treatments for COVID-19. Patients with mild symptoms can recuperate with symptomatic care, however establishing treatment for severe to critically ill patients who can have a high mortality has been essential. Accordingly, the guidelines for COVID-19 treatme...
Source: Journal of Korean Medical Science - December 20, 2022 Category: Biomedical Science Authors: Do Hyeon Park Chang Kyung Kang Pyoeng Gyun Choe Nam Joong Kim Wan Beom Park Myoung-Don Oh Source Type: research

Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series.
Authors: Mitra AR, Fergusson NA, Lloyd-Smith E, Wormsbecker A, Foster D, Karpov A, Crowe S, Haljan G, Chittock DR, Kanji HD, Sekhon MS, Griesdale DEG Abstract BACKGROUND: Pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with high intensive care unit (ICU) mortality. We aimed to describe the clinical characteristics and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) in a Canadian setting. METHODS: We conducted a retrospective case series of critically ill patients with laboratory-confirmed SARS-CoV-2 infection consecutively admitted to 1 of 6 ICUs ...
Source: Canadian Medical Association Journal - May 29, 2020 Category: General Medicine Tags: CMAJ Source Type: research

Ad hoc announcement pursuant to Art. 53 LR Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news

Update: Caring for COVID-19 Patients in the Hospital
Severe cases of COVID-19 infections continue to necessitate hospitalization more than two and a half years after the pandemic first hit. A total of 26,996 patients were hospitalized with COVID-19 in the U.S. as of Nov. 30, 2022, according to the Centers for Disease Control and Prevention’s COVID-19 Tracker,1 with a seven-day average of new deaths at 317 as of Nov. 16, 2022. This is down 5.3% from the previous seven-day average. But in contrast to the panic, emergency response, and mobilization for the pandemic’s early stages and steepest surges, managing COVID-19 in the hospital today has become relatively straightforw...
Source: The Hospitalist - January 3, 2023 Category: Hospital Management Authors: Ronda Whitaker Tags: Clinical Guidelines COVID-19 Drug Therapy Hospital Medicine Source Type: research

Roche launches new blood gas digital solution designed to improve patient care
Basel, 15 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE mark availability of Roche v-TAC, a new digital diagnostic solution that allows clinicians to obtain results for arterial blood gas values from patients with respiratory or metabolic abnormalities via a simpler, less invasive venous puncture through the use of a digital algorithm. Blood gas analysis is typically used in hospital point of care (POC) settings, where quick and accurate results are needed. This includes emergency rooms, intensive care units and operating rooms. The analysis provides clinicians with information about a patient ’s p...
Source: Roche Media News - May 15, 2020 Category: Pharmaceuticals Source Type: news

Ad hoc announcement pursuant to Art. 53 LR Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
             Basel, 04 June 2020   - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 illness requires mechanical ventilation. “The F...
Source: Roche Media News - June 4, 2020 Category: Pharmaceuticals Source Type: news